Anlotinib
Links: https://www.cancernetwork.com/view/anlotinib-showed-efficacy-safety-patients-glioblastoma, https://www.sciencedirect.com/science/article/abs/pii/S0923753419305329, https://clinicaltrials.gov/ct2/results?cond=Glioblastoma&term=Anlotinib&cntry=&state=&city=&dist=
From Ben Williams Book: Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) that targets receptors involved in tumor growth and angiogenesis, such as VEGFR, FGFR, PDGFR, c-Kit, and Ret. Developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., anlotinib has shown promise in treating various cancers including NSCLC, soft tissue sarcoma, and renal cell carcinoma. It works by inhibiting angiogenesis and tumor proliferation pathways, reducing tumor growth and spread.
Preclinical studies have demonstrated that anlotinib can inhibit the growth of glioblastoma cells and reduce tumor angiogenesis. Clinical trials are ongoing to evaluate its safety and efficacy in patients with GBM. Initial findings suggest that anlotinib is well-tolerated and may provide benefits in controlling tumor growth and prolonging survival in patients with GBM.
Anlotinib is not yet FDA-approved and is currently available under investigation in clinical trials. Common side effects include hypertension, fatigue, hand-foot syndrome, diarrhea, proteinuria, and thyroid dysfunction. Further research and clinical data will help establish its role in the treatment of GBM and other cancers.
For more detailed information on anlotinib's clinical trial results and ongoing research, refer to the links provided.Property "Has original text" (as page type) with input value "Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) that targets receptors involved in tumor growth and angiogenesis, such as VEGFR, FGFR, PDGFR, c-Kit, and Ret. Developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., anlotinib has shown promise in treating various cancers including NSCLC, soft tissue sarcoma, and renal cell carcinoma. It works by inhibiting angiogenesis and tumor proliferation pathways, reducing tumor growth and spread.</br></br>Preclinical studies have demonstrated that anlotinib can inhibit the growth of glioblastoma cells and reduce tumor angiogenesis. Clinical trials are ongoing to evaluate its safety and efficacy in patients with GBM. Initial findings suggest that anlotinib is well-tolerated and may provide benefits in controlling tumor growth and prolonging survival in patients with GBM.</br></br>Anlotinib is not yet FDA-approved and is currently available under investigation in clinical trials. Common side effects include hypertension, fatigue, hand-foot syndrome, diarrhea, proteinuria, and thyroid dysfunction. Further research and clinical data will help establish its role in the treatment of GBM and other cancers.</br></br>For more detailed information on anlotinib's clinical trial results and ongoing research, refer to the links provided." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process.